Daniel Lynch

About

Daniel Lynch is a Venture Partner at Third Rock Ventures since May 2013. Daniel joined Third Rock Ventures in 2011 and serves as a Strategic Advisor across their portfolio. Daniel brings more than 25 years of experience in biotechnology and pharmaceutical companies and has taken active board roles in several of their portfolio companies: Mmember and Chairman of the Board of Directors at Bluebird Bio, Member and Executive Chairman of the Board of Directors at Blueprint Medicines, Member and Chairman of the Board of Directors at Eleven Biotherapeutics. In addition to his role at Third Rock, Daniel serves as Executive Chairman of the Board of Directors at BIND Therapeutics, Nimbus Discovery and RaNA Therapeutics. Prior to joining Third Rock, Daniel served as Chief Executive and Chief Financial Officer at ImClone Systems Corp. While at ImClone, he negotiated a major partnership with Bristol-Myers Squibb and led the company through a significant turnaround, helping restore its reputat

Investment Focus

Location

Boston, US